| Name | Title | Contact Details |
|---|
Alfa Wasserman is a Caldwell, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
LED Dental traces its roots back to the mid-1990s, when company founder Peter Whitehead began performing oral cancer research in conjunction with the British Columbia Cancer Agency (BCCA). In 2000, Peter and a fellow BCCA researcher were awarded patents for groundbreaking technologies they developed for detecting oral cancer. Peter ultimately formed LED Medical Diagnostics Inc. and it operating subsidiary, LED Dental, to focus on the advancement of these technologies. LED Dental, in concert with the BCCA, ultimately co-developed the patented VELscope® Vx Enhanced Oral Assessment System, a tissue fluorescence visualization technology that received FDA and Health Canada clearance in 2006. Since then, there have been more than 12,000 VELscope Vx systems sold globally, and they have been used to perform more than 25 million oral examinations worldwide. In early 2014, LED Dental entered the dental imaging market in response to the explosive growth in dental CAD/CAM and the shift away from film-based systems to faster, more efficient and higher quality digital imaging solutions. We serve a previously unmet market demand for "open architecture" digital imaging technologies and we are rapidly growing a comprehensive portfolio of state-of-the-art offerings to meet this demand. Guiding our growth is a management team comprised some of the best minds from both the clinical and business sides of the dental industry. Drawing upon their decades of collective experience, they are identifying target technologies and product lines for our portfolio; building and managing our operations and sales teams; and developing a streamlined chain of communication that enables us to listen closely and serve the needs of our customers - and, in turn, enabling these clients to best serve their patients.
Desert AIDS Project is a Palm Springs, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NanoHybrids specializes in research and commercialization of nanotechnology-based products that enhance diagnosis and therapy for cancer and other diseases through enhanced molecular imaging and profiling. Our molecular imaging nanoparticles enhance contrast in vitro and in vivo across multiple biomedical imaging modalities. We are the leading provider of silica-coated gold nanoparticles optimized for photoacoustic (optoacoustic) imaging. With conjugation services we provide nanoparticles with high specificity for targeted cell receptors and tailored to individual applications. Our nanoparticles improve signal strength and allow real time imaging of functional biology. Interested in learning how we are using nanotechnology to drive advances in the life-sciences? Want learn more about our research, products, or services? Contact us, and let`s talk.
Founded in 1988 in Queensbury, N.Y., U.S., AngioDynamics is today a NASDAQ-listed public company. We are a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. Our diverse product line includes market-leading radiofrequency ablation and NanoKnife® systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. AngioDynamics has distinguished itself as a dynamic brand in a technologically competitive, high-growth industry, through the company`s consistent ability to successfully develop and bring to market new technologies and products. AngioDynamics believes it is well poised to continue that trend. Looking into the future, the company plans to bring forth a continuing stream of innovations that greatly improve patient care by providing the highest-quality, best-performing products.